Toronto academic hospital providing clinical expertise in neonatal intensive care, family-integrated care models, and basic cell biology research.
Mount Sinai Hospital is a major academic medical centre in Toronto, Canada, combining frontline clinical care with translational research. In H2020, they participated exclusively as a third party — meaning they hosted international researchers and provided clinical expertise without receiving direct EC funding. Their contributions span two distinct domains: fundamental cell biology (centriolar satellite function) and clinical implementation of family-centred neonatal care in ICU settings. The hospital's value in European consortia lies in providing a non-European clinical benchmark and access to Canadian patient populations and care protocols.
RISEinFAMILY (2021–2025) focused on implementing the FICare model — involving parents as active caregivers — across NICUs in multiple countries, with MSH as a clinical reference site.
RISEinFAMILY keywords include cost-effectiveness, value of implementation, equity, and training — indicating MSH contributes to how care models are evaluated and scaled, not just tested.
SATBIOFUN (2016–2019) used genome editing to study spatiotemporal biogenesis of centriolar satellites, a niche basic-science area where MSH hosted MSCA fellowship research.
RISEinFAMILY keywords — humanization of care, parents, nursing, perspective — reflect a growing institutional emphasis on placing families at the centre of hospital care delivery.
In the first half of their H2020 participation (2016–2019), MSH's only project involvement was in fundamental cell biology — specifically genome editing to study centriolar satellite dynamics, with no clinical or social keywords at all. By 2021–2025, their focus had shifted entirely to clinical and implementation research: family-integrated neonatal care, equity in access, training healthcare staff, and measuring real-world cost-effectiveness. This is a significant pivot from bench science to bedside and systems-level healthcare delivery.
MSH is moving toward clinical implementation science and family-centred care models — a direction that intersects with health systems reform, nursing practice, and health equity, suggesting future collaboration potential in those areas.
MSH has never led an H2020 project — both involvements are as a third party, the most peripheral participation role, typically meaning they hosted a researcher or provided data/infrastructure without being a contracted beneficiary. This reflects a common pattern for non-EU hospitals: European coordinators bring them in for their clinical expertise or patient access, not for administrative leadership. Working with MSH likely means engaging through a European partner who holds the formal consortium relationship.
Despite only two projects, MSH has connected with 13 unique consortium partners across 8 countries — a relatively broad network for such limited direct participation. Their third-party status suggests these connections are mediated through MSCA fellowship hosts rather than direct consortium relationships.
MSH is one of very few Canadian academic hospitals with documented H2020 involvement, making them a rare non-EU clinical reference point for European research consortia. For neonatal and family-integrated care specifically, they bring a North American implementation perspective that helps European projects validate whether their models travel across healthcare systems. Their dual presence in both basic science (MSCA-IF-GF fellowship hosting) and large-scale clinical implementation (MSCA-RISE) shows institutional breadth beyond a single research niche.
